Stock Events

Stock Events

ProMIS Neurosciences 

€9.05
0
-€0.3-3.21% Today

Statistics

Day High
9.05
Day Low
9
52W High
21.5
52W Low
6.15
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q4 2025
Next
-4.03
-2.99
-1.95
-0.9
Expected EPS
-0.9045934
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 23J.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Biogen is a direct competitor in the Alzheimer's disease treatment market, focusing on advanced biologics and therapies similar to ProMIS Neurosciences.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly is a competitor because of its significant investments in Alzheimer's disease research and development of related therapeutics, competing in the same space as ProMIS.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has been involved in the development of treatments for neurological disorders, including Alzheimer's, making it a competitor in the neurodegenerative disease sector.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. competes in the Alzheimer's disease treatment market with its research and development efforts in neurodegenerative diseases.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie is involved in neuroscience and specifically Alzheimer's disease research, making it a competitor in the development of neurodegenerative disease treatments.
Novartis
NVS
Mkt Cap279.67B
Novartis AG is a competitor due to its extensive research and development in neurodegenerative diseases, including Alzheimer's disease.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
ACADIA Pharmaceuticals focuses on the central nervous system disorders, including Alzheimer's, making it a competitor in the neuroscience field.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals, with its focus on RNA-targeted drug discovery and development, competes in the development of treatments for neurodegenerative diseases like Alzheimer's.

About

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Show more...
CEO
Mr. Eugene W. Williams
Employees
7
Country
Canada
ISIN
CA74346M5054

Listings

STU
DE
23J.STU
XNAS
US
PMN
F
DE
23J.F
BOATS
BOATS
PMN.BOATS

0 Comments

Share your thoughts

FAQ

What is ProMIS Neurosciences stock price today?▼
The current price of 23J.STU is €9.05 EUR — it has decreased by -3.21% in the past 24 hours. Watch ProMIS Neurosciences stock price performance more closely on the chart.
What is ProMIS Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ProMIS Neurosciences stocks are traded under the ticker 23J.STU.
Is ProMIS Neurosciences stock price growing?▼
23J.STU stock has fallen by -2.16% compared to the previous week, the month change is a +47.15% rise, over the last year ProMIS Neurosciences has showed a -27.02% decrease.
When is the next ProMIS Neurosciences earnings date?▼
ProMIS Neurosciences is going to release the next earnings report on May 18, 2026.
What were ProMIS Neurosciences earnings last quarter?▼
23J.STU earnings for the last quarter are -3.56 EUR per share, whereas the estimation was -4.03 EUR resulting in a +11.8% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does ProMIS Neurosciences have?▼
As of May 06, 2026, the company has 7 employees.
In which sector is ProMIS Neurosciences located?▼
ProMIS Neurosciences operates in the Health & Wellness sector.
When did ProMIS Neurosciences complete a stock split?▼
The last stock split for ProMIS Neurosciences was on November 28, 2025 with a ratio of 1:25.
Where is ProMIS Neurosciences headquartered?▼
ProMIS Neurosciences is headquartered in Toronto, Canada.